PhRMA, industry players urge Supreme Court to overturn abortion pill restrictions

If there’s one thing a wide swath of industry players can agree on, it’s that the FDA’s drug approval process represents the gold standard for drug regulation.

But if an appeals court’s August ruling on the abortion pill mifepristone holds up, the agency’s decision-making power could be undermined by the courts.